JP2022512851A5 - - Google Patents

Info

Publication number
JP2022512851A5
JP2022512851A5 JP2021523335A JP2021523335A JP2022512851A5 JP 2022512851 A5 JP2022512851 A5 JP 2022512851A5 JP 2021523335 A JP2021523335 A JP 2021523335A JP 2021523335 A JP2021523335 A JP 2021523335A JP 2022512851 A5 JP2022512851 A5 JP 2022512851A5
Authority
JP
Japan
Prior art keywords
antibody
pharmaceutical composition
composition according
light chain
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021523335A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512851A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/059581 external-priority patent/WO2020096915A1/en
Publication of JP2022512851A publication Critical patent/JP2022512851A/ja
Publication of JP2022512851A5 publication Critical patent/JP2022512851A5/ja
Priority to JP2024178276A priority Critical patent/JP2025004212A/ja
Pending legal-status Critical Current

Links

JP2021523335A 2018-11-05 2019-11-04 がんの処置のための抗tigit抗体の投薬レジメン Pending JP2022512851A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024178276A JP2025004212A (ja) 2018-11-05 2024-10-10 がんの処置のための抗tigit抗体の投薬レジメン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862755805P 2018-11-05 2018-11-05
US62/755,805 2018-11-05
PCT/US2019/059581 WO2020096915A1 (en) 2018-11-05 2019-11-04 Dosing regimen of anti-tigit antibody for treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024178276A Division JP2025004212A (ja) 2018-11-05 2024-10-10 がんの処置のための抗tigit抗体の投薬レジメン

Publications (2)

Publication Number Publication Date
JP2022512851A JP2022512851A (ja) 2022-02-07
JP2022512851A5 true JP2022512851A5 (cg-RX-API-DMAC7.html) 2022-11-16

Family

ID=70611082

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021523335A Pending JP2022512851A (ja) 2018-11-05 2019-11-04 がんの処置のための抗tigit抗体の投薬レジメン
JP2024178276A Withdrawn JP2025004212A (ja) 2018-11-05 2024-10-10 がんの処置のための抗tigit抗体の投薬レジメン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024178276A Withdrawn JP2025004212A (ja) 2018-11-05 2024-10-10 がんの処置のための抗tigit抗体の投薬レジメン

Country Status (10)

Country Link
US (1) US20210403557A1 (cg-RX-API-DMAC7.html)
EP (1) EP3877418A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022512851A (cg-RX-API-DMAC7.html)
KR (1) KR20210091209A (cg-RX-API-DMAC7.html)
CN (1) CN113302204A (cg-RX-API-DMAC7.html)
AU (1) AU2019375409A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021008582A8 (cg-RX-API-DMAC7.html)
CA (1) CA3118964A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021005236A (cg-RX-API-DMAC7.html)
WO (1) WO2020096915A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009126688A2 (en) 2008-04-09 2009-10-15 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
WO2021257124A1 (en) * 2020-06-18 2021-12-23 Genentech, Inc. Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
EP4219553A4 (en) * 2020-09-22 2024-11-27 Nanjing Sanhome Pharmaceutical Co., Ltd. ANTI-TIGIT ANTIBODIES AND DUAL ANTIBODIES AND THEIR APPLICATION
JP2024532744A (ja) * 2021-08-10 2024-09-10 メルク・シャープ・アンド・ドーム・エルエルシー T1gitアンタゴニスト、pd-1アンタゴニスト、及び(1又は複数の)化学療法剤を含む治療的組合せ
US20250064794A1 (en) * 2021-08-10 2025-02-27 Eisai R&D Management Co., Ltd. A therapeutic combination comprising a tigit antagonist, a pd-1 antagonist, and lenvatinib
WO2024211551A1 (en) 2023-04-06 2024-10-10 Glaxosmithkline Intellectual Property (No.4) Limited Methods for treating and monitoring cancer
WO2025128499A1 (en) * 2023-12-12 2025-06-19 Merck Sharp & Dohme Llc Combination therapy of a pd-1 antagonist and lag3 antagonist and all-trans retinoic acid or a pharmaceutically acceptable salt thereof for treating patients with cancer
CN118671353A (zh) * 2024-05-30 2024-09-20 中国人民解放军总医院第一医学中心 用于ais诊断的生物标志物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3689369A1 (en) * 2013-03-15 2020-08-05 Amgen, Inc Methods for treating psoriasis using an anti-il-23 antibody
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
CA2957722C (en) * 2014-08-19 2022-05-31 Merck Sharp & Dohme Corp. Anti-tigit antibodies
AR103268A1 (es) * 2014-12-23 2017-04-26 Bristol Myers Squibb Co Anticuerpos contra tigit
HRP20201334T1 (hr) * 2015-04-17 2020-11-27 Bristol-Myers Squibb Company Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba
SG10202007764TA (en) * 2015-09-25 2020-09-29 Genentech Inc Anti-tigit antibodies and methods of use
CA3025391A1 (en) * 2016-05-26 2017-11-30 Merck Patent Gmbh Pd-1 / pd-l1 inhibitors for cancer treatment
WO2018222718A1 (en) * 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Treatment of lag-3 positive tumors
US20210363243A1 (en) * 2018-02-01 2021-11-25 Merck Sharp & Dohme Corp. Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-lag3 antibody, and an anti-tigit antibody

Similar Documents

Publication Publication Date Title
JP2017514795A5 (cg-RX-API-DMAC7.html)
JP2013520442A5 (cg-RX-API-DMAC7.html)
JP2017501167A5 (cg-RX-API-DMAC7.html)
JP2018527383A5 (cg-RX-API-DMAC7.html)
JP2019519499A5 (cg-RX-API-DMAC7.html)
JP2017533912A5 (cg-RX-API-DMAC7.html)
JP2017507900A5 (cg-RX-API-DMAC7.html)
JP2020508317A5 (cg-RX-API-DMAC7.html)
JP2020514310A5 (cg-RX-API-DMAC7.html)
JP2021513540A5 (cg-RX-API-DMAC7.html)
HRP20231156T1 (hr) Kombinacija anti-pd-1 antitijela i bispecifičnih anti-cd20/anti-cd3 antitijela za liječenje raka
JP2017514461A5 (cg-RX-API-DMAC7.html)
JP2018070648A5 (cg-RX-API-DMAC7.html)
JP2018516969A5 (cg-RX-API-DMAC7.html)
JP2019515008A5 (cg-RX-API-DMAC7.html)
JP2020503273A5 (cg-RX-API-DMAC7.html)
JP2015532292A5 (cg-RX-API-DMAC7.html)
JP2021528423A5 (cg-RX-API-DMAC7.html)
JP2018534933A5 (cg-RX-API-DMAC7.html)
JP2019506403A5 (cg-RX-API-DMAC7.html)
JP2014533279A5 (cg-RX-API-DMAC7.html)
RU2018111529A (ru) Комбинированная терапия для лечения рака
JP2018536632A5 (ja) B7‐h3に特異的に結合する分子及びpd‐1に特異的に結合する分子
JP2017501157A5 (cg-RX-API-DMAC7.html)
JP2018518454A5 (cg-RX-API-DMAC7.html)